Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
Moliner, L Spurgeon, Laura Califano, Raffaele
Moliner, L
Spurgeon, Laura
Califano, Raffaele
Citations
Altmetric:
Abstract
None
Description
Date
2023
Publisher
Collections
Keywords
Type
Other
Citation
Moliner L, Spurgeon L, Califano R. Controversies in NSCLC: which second-line strategy after chemo-immunotherapy? ESMO open. 2023 Feb 13;8(2):100879. PubMed PMID: 36791668. Pubmed Central PMCID: PMC9958277 Myers Squibb, Roche, Merck Sharp & Dohme, Boehringer Ingelheim, Takeda, Bayer, Sanofi, Pharmamar, Lilly Oncology, Janssen, Amgen, and Novartis. All other authors have declared no conflicts of interest. Epub 2023/02/16. eng.